Cholangiocarcinoma (CCA) originates from the biliary tract. CCA is associated with a high mortality rate and a concerning increase in incidence. Here we show that for effective management of CCA, targeted therapy for precision medicine must be used in clinical practice. Despite the increasing numbers of clinical studies in CCA, targeted therapy drugs rarely get approved for clinical use. Here, we discuss the shortcomings of the conventional clinical trial process and propose the implementation of a novel co-clinical trial platform to expedite the drug development process in CCA. In co-clinical trials, the preclinical studies and clinical trials are conducted simultaneously to customize treatment for patients. Co-clinical trials are expected to improve the outcomes of clinical trials and encourage the approval of targeted therapy drugs in CCA. The increased availability of targeted therapy drugs for treatment is expected to facilitate the application of precision medicine in CCA.
Reference
Balasubramanian B, Venkatraman S, Myint KZ, Janvilisri T, Wongprasert K, Kumkate S, Bates DO, Tohtong R. Co-Clinical Trials: An Innovative Drug Development Platform for Cholangiocarcinoma. Pharmaceuticals. 2021 Jan;14(1):51. PMID: 33440754
DOI: 10.3390/ph14010051
| Relevant SDGs | |
|---|---|
 |
|
| BC investigator | |
 Assoc. Prof. Rutaiwan Tohtong |
|